Home > Publications database > GABA A receptor family: overview on structural characterization > print

001     861855
005     20240625095127.0
024 7 _ |a 10.4155/fmc-2018-0336
|2 doi
024 7 _ |a 1756-8919
|2 ISSN
024 7 _ |a 1756-8927
|2 ISSN
024 7 _ |a pmid:30801199
|2 pmid
024 7 _ |a WOS:000465356900007
|2 WOS
037 _ _ |a FZJ-2019-02276
082 _ _ |a 540
100 1 _ |a Amundarain, María Julia
|0 P:(DE-HGF)0
|b 0
245 _ _ |a GABA A receptor family: overview on structural characterization
260 _ _ |a London
|c 2019
|b Future Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1560416416_27296
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The pentameric γ-aminobutyric acid type A receptors are ion channels activated by ligands, which intervene in the rapid inhibitory transmission in the mammalian CNS. Due to their rich pharmacology and therapeutic potential, it is essential to understand their structure and function thoroughly. This deep characterization was hampered by the lack of experimental structural information for many years. Thus, computational techniques have been extensively combined with experimental data, in order to undertake the study of γ-aminobutyric acid type A receptors and their interaction with drugs. Here, we review the exciting journey made to assess the structures of these receptors and outline major outcomes. Finally, we discuss the brand new structure of the α1β2γ2 subtype and the amazing advances it brings to the field.
536 _ _ |a 574 - Theory, modelling and simulation (POF3-574)
|0 G:(DE-HGF)POF3-574
|c POF3-574
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Ribeiro, Rui Pedro
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Costabel, Marcelo Daniel
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Giorgetti, Alejandro
|0 P:(DE-Juel1)165199
|b 3
|e Corresponding author
773 _ _ |a 10.4155/fmc-2018-0336
|g Vol. 11, no. 3, p. 229 - 245
|0 PERI:(DE-600)2572258-X
|n 3
|p 229 - 245
|t Future medicinal chemistry
|v 11
|y 2019
|x 1756-8927
856 4 _ |u https://juser.fz-juelich.de/record/861855/files/Amundarain%20et%20al.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/861855/files/Amundarain%20et%20al.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:861855
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)165199
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-574
|2 G:(DE-HGF)POF3-500
|v Theory, modelling and simulation
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FUTURE MED CHEM : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IAS-5-20120330
|k IAS-5
|l Computational Biomedicine
|x 0
920 1 _ |0 I:(DE-Juel1)INM-9-20140121
|k INM-9
|l Computational Biomedicine
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)IAS-5-20120330
980 _ _ |a I:(DE-Juel1)INM-9-20140121
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21